Stay updated on Pembrolizumab Neoadjuvant in HCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Neoadjuvant in HCC Clinical Trial page.

Latest updates to the Pembrolizumab Neoadjuvant in HCC Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedThe page lists Masatoshi Kudo as the investigator (without the institution) and introduces Last verified metadata, while adding help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and updating the revision from v3.5.5 to v3.6.0.SummaryDifference2%

- Check19 days agoChange DetectedRevision badge updated from v3.5.4 to v3.5.5, representing a minor page update without changes to study content or results.SummaryDifference0.1%

- Check40 days agoChange DetectedA new revision tag 'Revision: v3.5.4' was added and the previous tag 'Revision: v3.5.3' was removed, updating the page's revision history.SummaryDifference0.1%

- Check62 days agoChange DetectedThe page’s revision/version number was updated from v3.5.2 to v3.5.3. This indicates a site build or metadata update without changing the underlying study information presented.SummaryDifference0.1%

- Check69 days agoChange DetectedSystem revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check98 days agoChange Detected- Added the disease term 'Hepatocellular carcinoma' and a new resource link to the Genetic and Rare Diseases Information Center. - Updated the site revision from v3.4.3 to v3.5.0.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Neoadjuvant in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Neoadjuvant in HCC Clinical Trial page.